The aim was to shorten the process by reducing the need for price negotiations as part of the tripartite discussions between Roche, Sweden’s regional authorities and TLV.
This is the first time Roche has used the model, which the company calls “Prutat och klart” – roughly translated as “Negotiated and ready” – for a medicine in Sweden.